Very promising isn't enough.
My company had studies on drugs where the first studies went really well even on humans.
Millions were invested and big studies established just to get a big disappointment in phase 3.
It went so far as that we thought a new drug would join the portfolio very soon, and than some months later came a big, big no.
https://www.reuters.com/article/us-n...-idUSKBN2B10HC
So am very cautious with my expectations.